Printer Friendly
The Free Library
19,607,053 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Enzon Announces New Executive Share Ownership Guidelines.


BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced a new policy regarding share ownership guidelines guidelines,
n.pl a set of standards, criteria, or specifications to be used or followed in the performance of certain tasks.
 that are applicable to the Company's executive officers and other members of senior management. Under the Company's new share ownership guidelines, members of senior management are required to acquire and maintain share holdings in Enzon common stock in amounts expressed as a multiple of each executive's base salary. "These new ownership guidelines will further align the compensation of our most senior executives with the Company's performance and the interests of our shareholders," commented Jeffrey H. Buchalter, Enzon's chairman & chief executive officer.

About Enzon

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics therapeutics

Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry.
 to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere.  by Enzon's specialized spe·cial·ize  
v. spe·cial·ized, spe·cial·iz·ing, spe·cial·iz·es

v.intr.
1. To pursue a special activity, occupation, or field of study.

2.
 sales force. Enzon's science-driven strategy includes an extensive drug development program that leverages the Company's macromolecular mac·ro·mol·e·cule  
n.
A very large molecule, such as a polymer or protein, consisting of many smaller structural units linked together. Also called supermolecule.
 engineering technology platforms, including PEG modification and single-chain antibody (SCA (Single Connector Attachment) An 80-pin plug and socket used to connect peripherals. With a SCSI drive, it rolls three cables (power, data channel and ID configuration) into one connector for fast installation and removal. (R)) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds. Further information about Enzon can be found on the Company's web site at www.enzon.com.

All information in this press release is as of July 27, 2005 and the Company undertakes no duty to update this information.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 27, 2005
Words:239
Previous Article:Platinum Equity Signs Agreement to Acquire Supply Chain Business from LESCO Inc.
Next Article:Advanced Power Technology to Present at the RBC Capital Markets North American Technology Conference.



Related Articles
Enzon announces final conversion of Series B Convertible Preferred Stock.
Enzon's CEO Announces Plan to Exercise Expiring Options.
Enzon Acquires Abelcet North American Business From Elan Transaction Bolsters Bottom Line and Marks a Significant Step Toward Full Integration.
Enzon Completes Acquisition of Abelcet North American Business From Elan.
Enzon And SkyePharma Form Strategic Alliance; Enzon Licenses North American rights to SkyePharma's DepoCyt.
Enzon Reports on Clinical Development Program.
Enzon Pharmaceuticals Reports Third Quarter Financial Results; Total Revenues Increase by 118% and Phase II Clinical Trials Initiated for PROTHECAN...
ENZON/INEX SIGN COMMERCIALIZATION PACT FOR ONCOLOGY DRUG ONCO TCS.
Enzon Reports Second Quarter Results.
Enzon Reports Certain Financial and Other Information for Fourth Quarter of Fiscal 2005; Fourth Quarter Revenues of $44 Million; Cash Reserves Remain...

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles